AnaptysBio(ANAB)

Focus: AnaptysBio is a San Diego-based public biotechnology company focused on antibody therapeutics for oncology and inflammatory diseases. The company is in early-stage development with a pre-commercial pipeline and minimal revenue generation.

Oncology

Profile data last refreshed 17h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About AnaptysBio

AI assessmentNot Hiring

No open roles listed right now. Follow AnaptysBio to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$17M

Pipeline & Clinical Trials

Analysis of Peripheral Blood ILC2s and Th2 Cells in Response to ANB020

Asthma

N/A

Clinical Trials (1)

NCT04256044Analysis of Peripheral Blood ILC2s and Th2 Cells in Response to ANB020

N/A

Help build intelligence for AnaptysBio

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage antibody platform with multiple Phase 2 programs in high-value indications (eosinophilic asthma, atopic dermatitis, alopecia areata)
Public company status provides equity upside potential and structural stability compared to pre-revenue private biotech
Concentrated R&D focus (771% R&D intensity) signals commitment to pipeline advancement and scientific rigor

Watch Out For

Severe cash burn: $132M R&D spend against only $17M revenue (FY2025) with mounting net losses approaching $164M annually
Zero Phase 3 programs and no commercial pipeline; no near-term revenue catalysts or product approvals expected
Currently no open job postings (activeJobCount=0) and evidence of potential spin-off activity suggests organizational uncertainty

Generated by Claude from AnaptysBio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

etokimab

Eosinophilic Asthma

Phase 2

Clinical Trials (4)

NCT03614923Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Phase 2

NCT03533751Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Phase 2

NCT02920021Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy

Phase 2

+1 more

ANB032

Atopic Dermatitis

Phase 2

Clinical Trials (1)

NCT05935085This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).

Phase 2

rosnilimab

Alopecia Areata

Phase 2

Clinical Trials (3)

NCT06041269A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)

Phase 2

NCT05205070A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata

Phase 2

NCT06127043A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2013

Portfolio: 9 clinical trials

Top TAs: Immunology, Respiratory, Dermatology

Publications: 24 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

Immunology

4 pipeline

Respiratory

2 pipeline

Dermatology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$17M67%

R&D Spend

$132M(771%)49%

Net Income

-$164M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Risk Signals

Spin-off announcement (April 2026) suggests potential workforce restructuring, though specific layoff details not disclosed.

Corporate restructuring risk is elevated; job security for new hires is uncertain pending spin-off clarity.

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Immune Checkpoint Agonists for Inflammatory Skin Diseases.

The Journal of investigative dermatology

2025

PMID:39927905

Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial.

The British journal of dermatology

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

AnaptysBio(ANAB)

About AnaptysBio

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · AnaptysBio(10)

Open Jobs (0)

Financials (FY2025)

Hiring Trend

Risk Signals

Research Publications(10)